Home > Focus Areas > NSCLC Connect > Post
  • Saved

3yr
Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan - PubMed

Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35524869/

doi: 10.1007/s00520-022-07102-6. Online ahead of print. 1 Department of Pharmacy, Toyota Kosei Hospital, 500-1, Ibobara, Jousui-cho, Toyota, 470-0396, Japan. [email protected]. 2 Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan. [email protected]. 3 Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Daigaku-nishi 1-25-4, Gifu, 501-1196, Japan.


Conclusion: Peg-G is not cost-effective in patients with NSCLC receiving RAM DTX in Japan.

  • 3yr
    Not cost effective??? How ethical a measure is that?? In a free society, the individual gets to determine what is cost effective. In an unethical immoral society, the 'system' gets to determine this. Another way to state this: The most basic question is not what is best, but who shall decide what is best."-Thomas Sowell
  • 3yr
    Japan is cheap and chemo generally at specialized centers

You might also like